參考文獻
Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int (1995) 47(6):1703-20.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet (1997a) 349(9069):1857-63.
Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet (1997b) 349(9068):1787-92.
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med (1997c) 157(21):2413-46.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Bmj (1998a) 317(7160):713-20.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998b) 352(9131):837-53.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Bmj (1998c) 317(7160):703-13.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet (2000) 355(9200):253-9.
Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med (2001) 134(5):370-9.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis (2002) 39(2 Suppl 2):S1-246. t&artType=abs&id=a30940&target=.
Abbate, M., Zoja, C., Rottoli, D., et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol (1999) 10(4):804-13.
Agarwal, R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int (2001) 59(6):2282-9.
Agodoa, L., Eknoyan, G., Ingelfinger, J., et al. Assessment of structure and function in progressive renal disease. Kidney Int Suppl (1997) 63:S144-50.
Allen, A. M., Zhuo, J., and Mendelsohn, F. A. Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol (1999) 10 Suppl 11:S23-9.
Andersen, S., Tarnow, L., Rossing, P., et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int (2000) 57(2):601-6.
Anderson, S., Rennke, H. G., and Brenner, B. M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest (1986) 77(6):1993-2000.
Arauz-Pacheco, C., Parrott, M. A., and Raskin, P. The treatment of hypertension in adult patients with diabetes. Diabetes Care (2002) 25(1):134-47.
Bakris, G. L. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med (1990) 112(9):707-8.
Bakris, G. L., Copley, J. B., Vicknair, N., et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int (1996) 50(5):1641-50.
Bakris, G. L., Mangrum, A., Copley, J. B., et al. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension (1997) 29(3):744-50.
Bakris, G. L., Siomos, M., Richardson, D., et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int (2000a) 58(5):2084-92.
Bakris, G. L., and Smith, A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med (1996) 125(3):201-4.
Bakris, G. L., Williams, M., Dworkin, L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis (2000b) 36(3):646-61.
Basta, E., and Bakris, G. L. Evolution of drugs that preserve renal function. J Clin Pharmacol (2000) 40(9):978-89.
Brenner, B. M., Cooper, M. E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 345(12):861-9.
Brenner, B. M., Meyer, T. W., and Hostetter, T. H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med (1982) 307(11):652-9.
Brown, N. J., Nakamura, S., Ma, L., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int (2000) 58(3):1219-27.
Burgess, E. Conservative treatment to slow deterioration of renal function: evidence-based recommendations. Kidney Int Suppl (1999) 70:S17-25.
Burnier, M. Angiotensin II type 1 receptor blockers. Circulation (2001) 103(6):904-12.
Burnier, M., and Brunner, H. R. Angiotensin II receptor antagonists. Lancet (2000) 355(9204):637-45.
Burns, K. D. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis (2000) 36(3):449-67.
Carey, R. M., Wang, Z. Q., and Siragy, H. M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension (2000) 35(1 Pt 2):155-63.
Chan, J. C., Cockram, C. S., Nicholls, M. G., et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. Bmj (1992) 305(6860):981-5.
Coggins, C. H., Breyer Lewis, J., Caggiula, A. W., et al. Differences between women and men with chronic renal disease. Nephrol Dial Transplant (1998) 13(6):1430-7.
Cremer, W., and Bock, K. D. Symptoms and course of chronic hypokalemic nephropathy in man. Clin Nephrol (1977) 7(3):112-9.
Davis, B. R., Cutler, J. A., Gordon, D. J., et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens (1996) 9(4 Pt 1):342-60.
De Cesaris, R., Ranieri, G., Filitti, V., et al. Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. J Cardiovasc Pharmacol (1993) 22(2):208-14.
Elving, L. D., de Nobel, E., van Lier, H. J., et al. A comparison of the hypotensive effects of captopril and atenolol in the treatment of hypertension in diabetic patients. J Clin Pharmacol (1989) 29(4):316-20.
Estacio, R. O., Jeffers, B. W., Hiatt, W. R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med (1998) 338(10):645-52.
Ferrari, P., Marti, H. P., Pfister, M., et al. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens (2002) 20(1):125-30.
Fogo, A. B. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis (2000) 35(2):179-88.
Gansevoort, R. T., Sluiter, W. J., Hemmelder, M. H., et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta- analysis of comparative trials. Nephrol Dial Transplant (1995) 10(11):1963-74.
Garza, R., Medina, R., Basu, S., et al. Predictors of the rate of renal function decline in non-insulin- dependent diabetes mellitus. Am J Nephrol (1997) 17(1):59-67.
Giatras, I., Lau, J., and Levey, A. S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med (1997) 127(5):337-45.
Goldberg, A., and Sweet, C. Efficacy and safety of losartan. Can J Cardiol (1995) 11 Suppl F:27F-32F.
Gress, T. W., Nieto, F. J., Shahar, E., et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med (2000) 342(13):905-12.
Hannedouche, T., Landais, P., Goldfarb, B., et al. Randomised controlled trial of enalapril and beta blockers in non- diabetic chronic renal failure. Bmj (1994) 309(6958):833-7.
Hansson, L., Zanchetti, A., Carruthers, S. G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 351(9118):1755-62.
Hebert, L. A., Falkenhain, M. E., Nahman, N. S., Jr., et al. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol (1999) 19(1):1-6.
Hebert, L. A., Wilmer, W. A., Falkenhain, M. E., et al. Renoprotection: one or many therapies? Kidney Int (2001) 59(4):1211-26.
Heeg, J. E., de Jong, P. E., van der Hem, G. K., et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int (1989) 36(2):272-9.
Holdaas, H., Hartmann, A., Berg, K. J., et al. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant (1998) 13(12):3096-102.
Hollenberg, N. K. Renal implications of angiotensin receptor blockers. Am J Hypertens (2001) 14(7 Pt 2):237S-241S.
Hoogeveen, E. K., Kostense, P. J., Jager, A., et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int (1998) 54(1):203-9.
Jafar, T. H., Schmid, C. H., Landa, M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med (2001) 135(2):73-87.
Jungers, P., Hannedouche, T., Itakura, Y., et al. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant (1995) 10(8):1353-60.
Kasiske, B. L., Kalil, R. S., Ma, J. Z., et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med (1993) 118(2):129-38.
Keane, W. F., and Eknoyan, G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis (1999) 33(5):1004-10.
Kincaid-Smith, P., Fairley, K., and Packham, D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant (2002) 17(4):597-601.
Klag, M. J., Whelton, P. K., Randall, B. L., et al. Blood pressure and end-stage renal disease in men. N Engl J Med (1996) 334(1):13-8.
Klag, M. J., Whelton, P. K., Randall, B. L., et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. Jama (1997) 277(16):1293-8.
Klahr, S., Levey, A. S., Beck, G. J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med (1994) 330(13):877-84.
Kloke, H. J., Branten, A. J., Huysmans, F. T., et al. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int (1998) 53(6):1559-73.
Kokkonen, J. O., Saarinen, J., and Kovanen, P. T. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation (1997) 95(6):1455-63.
Kubo, M., Kiyohara, Y., Kato, I., et al. Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. Kidney Int (1999) 55(6):2450-6.
Kuriyama, S., Tomonari, H., Yoshida, H., et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron (1997) 77(2):176-85.
Kurtzman, N.A., Laski, M.E., Pressley, T. A., et al. Excerpts from the United States Renal Data System 2001 Annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis (2001) 38(Suppl 3):S37-S203
Lacourciere, Y., Belanger, A., Godin, C., et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int (2000) 58(2):762-9.
Lacourciere, Y., Nadeau, A., Poirier, L., et al. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension (1993) 21(6 Pt 1):786-94.
Laffel, L. M., McGill, J. B., and Gans, D. J. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med (1995) 99(5):497-504.
Lau, K. Phosphate excess and progressive renal failure: the precipitation- calcification hypothesis. Kidney Int (1989) 36(5):918-37.
Lazarus, J. M., Bourgoignie, J. J., Buckalew, V. M., et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension (1997) 29(2):641-50.
Lebovitz, H. E., Wiegmann, T. B., Cnaan, A., et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl (1994) 45:S150-5.
Leehey, D. J., Singh, A. K., Alavi, N., et al. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl (2000) 77:S93-8.
Levin, A. Identification of patients and risk factors in chronic kidney disease-- evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant (2001) 16(Suppl 7):57-60.
Lewis, E. J., Hunsicker, L. G., Bain, R. P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 329(20):1456-62.
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 345(12):851-60.
Lewis, J. B., Berl, T., Bain, R. P., et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis (1999) 34(5):809-17.
Mailloux, L. U., and Haley, W. E. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis (1998) 32(5):705-19.
Mailloux, L. U., and Levey, A. S. Hypertension in patients with chronic renal disease. Am J Kidney Dis (1998) 32(5 Suppl 3):S120-41.
Martinez-Maldonado, M. Hypertension in end-stage renal disease. Kidney Int Suppl (1998) 68:S67-72.
Martinez-Maldonado, M. Role of hypertension in the progression of chronic renal disease. Nephrol Dial Transplant (2001) 16(Suppl 1):63-6.
Maschio, G., Alberti, D., Janin, G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting- Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med (1996) 334(15):939-45.
McConnaughey, M. M., McConnaughey, J. S., and Ingenito, A. J. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol (1999) 39(6):547-59.
Mezzano, S. A., Droguett, M. A., Burgos, M. E., et al. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int (2000) 57(1):147-58.
Mogensen, C. E. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia (1999) 42(3):263-85.
Mogensen, C. E., Neldam, S., Tikkanen, I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Bmj (2000) 321(7274):1440-4.
Mogensen, C. E., and Schmitz, O. The diabetic kidney: from hyperfiltration and microalbuminuria to end- stage renal failure. Med Clin North Am (1988) 72(6):1465-92.
Mora-Macia, J., Cases, A., Calero, F., et al. Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure. Nephrol Dial Transplant (2001) 16(Suppl 1):82-4.
Nair, K. S., Pabico, R. C., Truglia, J. A., et al. Mechanism of glomerular hyperfiltration after a protein meal in humans. Role of hormones and amino acids. Diabetes Care (1994) 17(7):711-5.
Neugarten, J., Acharya, A., and Silbiger, S. R. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol (2000) 11(2):319-29.
Nielsen, F. S., Rossing, P., Gall, M. A., et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes (1997) 46(7):1182-8.
Nelson RG, Knowler WC, Petritt DJ, Bennett PH: Kidney disease in diabetes. In Diabetes in America. 2nd ed. National Diabetes Data Group.Washington, DC, U.S. Govt. Printing Office, 1995(NIH publ.no.95-1468。
Nissenson, A. R., Collins, A. J., Hurley, J., et al. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol (2001) 12(8):1713-20.
Nomura, A., Morita, Y., Maruyama, S., et al. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol (1997) 151(2):539-47.
Noris, M., and Remuzzi, G. ACE inhibitors and AT1 receptor antagonists: is two better than one? Kidney Int (2002) 61(4):1545-7.
Oda, H., and Keane, W. F. Recent advances in statins and the kidney. Kidney Int Suppl (1999) 71:S2-5.
Ogrodowski, J. L., Hebert, L. A., Sedmak, D., et al. Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Int (1991) 40(6):1141-7.
Oparil, S., and Calhoun, D. A. Managing the patient with hard-to-control hypertension. Am Fam Physician (1998) 57(5):1007-14, 1019-20.
Orchard, T. J., Dorman, J. S., Maser, R. E., et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes (1990) 39(9):1116-24.
Orth, S. R., Stockmann, A., Conradt, C., et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int (1998) 54(3):926-31.
Parving, H. H., Lehnert, H., Brochner-Mortensen, J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 345(12):870-8.
Parving, H. H., Smidt, U. M., Hommel, E., et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis (1993) 22(1):188-95.
Perry, H. M., Jr., Miller, J. P., Fornoff, J. R., et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension (1995) 25(4 Pt 1):587-94.
Peterson, J. C., Adler, S., Burkart, J. M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 123(10):754-62.
Pinol, C., Cobos, A., Cases, A., et al. Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria. Kidney Int Suppl (1996) 55:S85-7.
Pisoni, R., Ruggenenti, P., and Remuzzi, G. Renoprotective therapy in patients with nondiabetic nephropathies. Drugs (2001) 61(6):733-45.
Praga, M. Slowing the progression of renal failure. Kidney Int (2002) 61 Suppl 80:18-22.
Ravid, M., Brosh, D., Levi, Z., et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med (1998) 128(12 Pt 1):982-8.
Ravid, M., Lang, R., Rachmani, R., et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow- up study. Arch Intern Med (1996) 156(3):286-9.
Refsum, H., Ueland, P. M., Nygard, O., et al. Homocysteine and cardiovascular disease. Annu Rev Med (1998) 49:31-62.
Reichard, P., Nilsson, B. Y., and Rosenqvist, U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med (1993) 329(5):304-9.
Remuzzi, G., and Bertani, T. Pathophysiology of progressive nephropathies. N Engl J Med (1998) 339(20):1448-56.
Remuzzi, G., Ruggenenti, P., and Benigni, A. Understanding the nature of renal disease progression. Kidney Int (1997) 51(1):2-15.
Remuzzi, G., Ruggenenti, P., and Perico, N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med (2002a) 136(8):604-15.
Remuzzi, G., Schieppati, A., and Ruggenenti, P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med (2002b) 346(15):1145-51.
Ridao, N., Luno, J., Garcia de Vinuesa, S., et al. Prevalence of hypertension in renal disease. Nephrol Dial Transplant (2001) 16(Suppl 1):70-3.
Ritz, S., Mehlan, G., and Martz, W. Postmortem diagnosis of diabetic metabolic derangement: elevated alpha 1-antitrypsin and haptoglobin glycosylation levels as an index of antemortem hyperglycemia. J Forensic Sci (1996) 41(1):94-100.
Rodgers, J. E., and Patterson, J. H. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm (2001) 58(8):671-83.
Rodicio, J. L., and Alcazar, J. M. Hypertension in chronic renal failure. J Hypertens (2001) 19(11):2111-4.
Rossing, P., Tarnow, L., Boelskifte, S., et al. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes (1997) 46(3):481-7.
Rovin, B. H., Dickerson, J. A., Tan, L. C., et al. Activation of nuclear factor-kappa B correlates with MCP-1 expression by human mesangial cells. Kidney Int (1995) 48(4):1263-71.
Rovin, B. H., Doe, N., and Tan, L. C. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis (1996) 27(5):640-6.
Ruggenenti, P., Gambara, V., Perna, A., et al. The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol (1998a) 9(12):2336-43.
Ruggenenti, P., Perna, A., Benini, R., et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol (1999a) 10(5):997-1006.
Ruggenenti, P., Perna, A., Gherardi, G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (1999b) 354(9176):359-64.
Ruggenenti, P., Perna, A., Gherardi, G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet (1998b) 352(9136):1252-6.
Ruggenenti, P., Perna, A., and Remuzzi, G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol (2001a) 12(12):2832-7.
Ruggenenti, P., Perna, A., Zoccali, C., et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). J Am Soc Nephrol (2000) 11(1):88-96.
Ruggenenti, P., Schieppati, A., and Remuzzi, G. Progression, remission, regression of chronic renal diseases. Lancet (2001b) 357(9268):1601-8.
Ruilope, L. RAS blockade: new possibilities in the treatment of complications of diabetes. Heart (2000) 84 Suppl 1:i32-4:discussion i50.
Ruilope, L. M., Aldigier, J. C., Ponticelli, C., et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens (2000) 18(1):89-95.
Ruilope, L. M., and Rodicio, J. L. The kidney in arterial hypertension. Nephrol Dial Transplant (2001) 16(Suppl 1):50-2.
Ruilope, L. M., and Schiffrin, E. L. Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use? Hypertension (2001) 38(3 Pt 2):537-42.
Ruilope, L. M., van Veldhuisen, D. J., Ritz, E., et al. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol (2001) 38(7):1782-7.
Russo, D., Minutolo, R., Pisani, A., et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis (2001) 38(1):18-25.
Russo, D., Pisani, A., Balletta, M. M., et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis (1999) 33(5):851-6.
Salvetti, A., Mattei, P., and Sudano, I. Renal protection and antihypertensive drugs: current status. Drugs (1999) 57(5):665-93.
Savage, S., Nagel, N. J., Estacio, R. O., et al. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis (1995) 25(6):836-44.
Schlondorff, D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int (1993) 44(3):643-53.
Schwenger, V., and Ritz, E. Audit of antihypertensive treatment in patients with renal failure. Nephrol Dial Transplant (1998) 13(12):3091-5.
Seliger, S. L., Davis, C., and Stehman-Breen, C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens (2001) 10(2):219-25.
Shiigai, T., and Shichiri, M. Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease. Am J Kidney Dis (2001) 37(3):477-83.
Silbiger, S. R., and Neugarten, J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis (1995) 25(4):515-33.
Song, J. C., and White, C. M. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy (2000) 20(2):130-9.
Taal, M. W., and Brenner, B. M. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int (2000) 57(5):1803-17.
Taal, M. W., and Brenner, B. M. Evolving strategies for renoprotection: non-diabetic chronic renal disease. Curr Opin Nephrol Hypertens (2001) 10(4):523-31.
Tarif, N., and Bakris, G. L. Angiotensin II receptor blockade and progression of nondiabetic- mediated renal disease. Kidney Int Suppl (1997) 63:S67-70.
Taylor, A. A. Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure? Curr Opin Nephrol Hypertens (2001) 10(5):643-8.
Terzi, F., Burtin, M., and Friedlander, G. Early molecular mechanisms in the progression of renal failure: role of growth factors and protooncogenes. Kidney Int Suppl (1998) 65:S68-73.
Velussi, M., Brocco, E., Frigato, F., et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes (1996) 45(2):216-22.
Vivian, E. M., and Goebig, M. L. Slowing the progression of renal disease in diabetic patients. Ann Pharmacother (2001) 35(4):452-63.
Williams, P. S., Fass, G., and Bone, J. M. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med (1988) 67(252):343-54.
Williams, P. S., Stevens, M. E., Fass, G., et al. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial. Q J Med (1991) 81(294):837-55.
Wilmer, W. A., Hebert, L. A., Lewis, E. J., et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis (1999) 34(2):308-14.
Wolf, G., and Ziyadeh, F. N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int (1999) 56(2):393-405.
洪輝榮。高血壓用藥處方型態之探討。國立成功大學臨床藥學研究所碩士論文。2001年6月。行政院衛生署: http://doh.gov.tw/
中央健保局: http://nhi.gov.tw/